Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia
This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.
1. A method of putatively determining whether an antibody or antigen binding fragment is suitable for use in treating or preventing Pituitary Adenylate Cyclase-Activating Peptide (PACAP)-associated photophobia or light aversion, or precluding the onset of PACAP-associated photophobia or light aversion, in a human subject in need thereof, which method comprises:
(i) providing at least one first non-human test subject and at least one non-human second test subject;
(ii) first administering PACAP to the at least one first non-human test subject and the at least one second non-human test subject;
(iii) subsequently administering to the at least one first non-human test subject who has been administered PACAP an anti-PACAP antibody or an antigen binding fragment thereof;
(iv) comparing the response of the at least one first non-human test subject and at least one second non-human test subject to light; and
(v) if said first at least one non-human test subject exhibits decreased light aversion or decreased photophobia as compared with the at least one second non-human test subject, identifying said antibody or antigen binding fragment as being putatively suitable for use in treating or preventing PACAP-associated photophobia or light aversion, or precluding the onset of PACAP-associated photophobia or light aversion in a human subject in need thereof;
wherein said anti-PACAP antibody or antigen binding fragment comprises an immunoglobulin variable heavy chain having the CDR1 sequence of SEQ ID NO: 44; a CDR2 sequence of SEQ ID NO: 46; and a CDR3 sequence of SEQ ID NO: 48; and/or an immunoglobulin variable light chain having the CDR1 sequence of SEQ ID NO: 64; a CDR2 sequence of SEQ ID NO: 66; and a CDR3 sequence of SEQ ID NO: 68.
2. A method of screening for an antibody or antigen binding fragment thereof suitable for use in treating or preventing Pituitary Adenylate Cyclase-Activating Peptide (PACAP)-associated photophobia or light aversion, or precluding the onset of PACAP-associated photophobia or light aversion, in a human subject in need thereof, which comprises:
(i) providing at least one first non-human test subject and at least one second non-human test subject;
(ii) first administering to the at least one first non-human test subject an anti-PACAP antibody or an antigen binding fragment thereof;
(iii) subsequently administering PACAP to the at least one first non-human test subject and the at least one second non-human test subject, wherein said first subject has previously been administered said anti-PACAP antibody or an antigen binding fragment thereof;
(iv) comparing the response of the at least one first non-human test subject and at least one second non-human test subject to light; and
(v) if said first at least one non-human test subject exhibits decreased light aversion or decreased photophobia as compared with the at least one second non-human test subject, identifying said antibody or antigen binding fragment as being putatively suitable for use in treating or preventing PACAP-associated photophobia or light aversion, or precluding the onset of PACAP-associated photophobia or light aversion in a human subject in need thereof;
wherein said anti-PACAP antibody or antigen binding fragment comprises an immunoglobulin variable heavy chain having the CDR1 sequence of SEQ ID NO: 44; a CDR2 sequence of SEQ ID NO: 46; and a CDR3 sequence of SEQ ID NO: 48; and/or an immunoglobulin variable light chain having the CDR1 sequence of SEQ ID NO: 64; a CDR2 sequence of SEQ ID NO: 66; and a CDR3 sequence of SEQ ID NO: 68.
3. The method of claim 1 or 2 , wherein the efficacy of said anti-PACAP antibody or antigen binding fragment thereof for putatively inhibiting PACAP-associated photophobia or light aversion, or precluding the onset of PACAP-associated photophobia or light aversion in a human subject in need thereof, is confirmed by administering said anti-PACAP antibody or antigen binding fragment to a human subject who comprises or chronically experiences photophobia or light aversion caused by a chronic condition associated with photophobia or light aversion and determining in said subject whether said anti-PACAP antibody or antigen binding fragment thereof inhibits PACAP-associated photophobia or light aversion, or precludes the onset or the frequency of onset of PACAP-associated photophobia or light aversion in said human subject who comprises or chronically experiences photophobia or light aversion caused by a condition associated with photophobia or light aversion.
4. The method of claim 1 or 2 , which comprises determining whether said anti-PACAP antibody or fragment thereof inhibits or diminishes light aversion behavior in a first rodent administered PACAP and said anti-PACAP antibody or antigen binding fragment thereof, as compared to a second rodent administered PACAP which is not administered said anti-PACAP antibody or antigen binding fragment thereof.
5. The assay of claim 1 or 2 wherein said anti-PACAP antibody is full-length.
6. The assay of claim 1 or 2 wherein said anti-PACAP antibody is humanized.
7. The assay of claim 1 or 2 wherein said anti-PACAP antibody comprises a human IgG1, IgG2, IgG3 or IgG4 constant region.
8. The assay of claim 1 or 2 wherein said anti-PACAP antibody comprises a human IgG1 constant region.
9. The assay of claim 1 or 2 wherein said anti-PACAP antibody is non-glycosylated.